Covid-19 in liver transplant recipients: the French SOT COVID registry
- PMID: 33636654
- PMCID: PMC7843027
- DOI: 10.1016/j.clinre.2021.101639
Covid-19 in liver transplant recipients: the French SOT COVID registry
Abstract
Background: Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information on its clinical presentation and prognosis in organ transplant recipients remains limited. The aim of this registry-based observational study was to report the characteristics and clinical outcomes of liver transplant (LT) recipients included in the French nationwide Registry of Solid Organ Transplant Recipients with Covid-19.
Methods: COVID-19 was diagnosed in patients who had a positive PCR assay for SARS-CoV-2 or in presence of typical lung lesions on imaging or specific SARS-CoV-2 antibodies. Clinical and laboratory characteristics, management of immunosuppression, treatment for Covid-19, and clinical outcomes (hospitalization, admission to intensive care unit, mechanical ventilation, or death) were recorded.
Results: Of the 104 patients, 67 were admitted to hospital and 37 were managed at home (including all 13 children). Hospitalized patients had a median age of 65.2 years (IQR: 58.1 - 73.2 years) and two thirds were men. Most common comorbidities included overweight (67.3%), hypertension (61.2%), diabetes (50.7%), cardiovascular disease (20.9%) and respiratory disease (16.4%). SARS-CoV-2 infection was identified after a median of 92.8 months (IQR: 40.1 - 194.7 months) from LT. During hospitalization, antimetabolites, mTOR inhibitor, and CNIs were withdrawn in 41.9%, 30.0% and 12.5% of patients, respectively. The composite endpoint of severe Covid-19 within 30 days after diagnosis was reached by 33.0% of the adult patients. The 30-day mortality rate was 20.0%, and 28.1% for hospitalized patients. Multivariate analysis identified that age was independently associated with mortality.
Conclusion: In our large nationwide study, Covid-19 in LT recipients was associated with a high mortality rate.
Keywords: Covid-19; Immunosuppression; Liver transplantation; Mortality; Prognosis.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Figures

Similar articles
-
An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants.Kidney Int. 2020 Dec;98(6):1549-1558. doi: 10.1016/j.kint.2020.08.005. Epub 2020 Aug 24. Kidney Int. 2020. PMID: 32853631 Free PMC article.
-
Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.Lancet Gastroenterol Hepatol. 2020 Nov;5(11):1008-1016. doi: 10.1016/S2468-1253(20)30271-5. Epub 2020 Aug 28. Lancet Gastroenterol Hepatol. 2020. PMID: 32866433 Free PMC article.
-
Is COVID-19 infection more severe in kidney transplant recipients?Am J Transplant. 2021 Mar;21(3):1295-1303. doi: 10.1111/ajt.16424. Epub 2021 Jan 28. Am J Transplant. 2021. PMID: 33259686 Free PMC article.
-
Clinical Presentation, Treatment, and Mortality Rate in Liver Transplant Recipients With Coronavirus Disease 2019: A Systematic Review and Quantitative Analysis.Transplant Proc. 2020 Nov;52(9):2676-2683. doi: 10.1016/j.transproceed.2020.07.012. Epub 2020 Jul 30. Transplant Proc. 2020. PMID: 32891405 Free PMC article.
-
SARS-CoV-2 infection in adult liver transplantation recipients: a systematic review of risk factors for mortality and immunosuppression role.Eur Rev Med Pharmacol Sci. 2023 Feb;27(4):1695-1707. doi: 10.26355/eurrev_202302_31413. Eur Rev Med Pharmacol Sci. 2023. PMID: 36876704
Cited by
-
Multidisciplinary Approaches for Transthyretin Amyloidosis.Cardiol Ther. 2021 Dec;10(2):289-311. doi: 10.1007/s40119-021-00222-w. Epub 2021 Jun 4. Cardiol Ther. 2021. PMID: 34089151 Free PMC article. Review.
-
Impact of COVID-19 on liver transplant recipients: A nationwide cohort study evaluating hospitalization, transplant rejection, and inpatient mortality.World J Transplant. 2024 Jun 18;14(2):90866. doi: 10.5500/wjt.v14.i2.90866. World J Transplant. 2024. PMID: 38947960 Free PMC article.
-
COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre study.Sci Rep. 2022 Mar 22;12(1):4831. doi: 10.1038/s41598-022-08947-x. Sci Rep. 2022. PMID: 35318432 Free PMC article.
-
Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis.Diseases. 2022 Dec 1;10(4):118. doi: 10.3390/diseases10040118. Diseases. 2022. PMID: 36547204 Free PMC article. Review.
-
Impact of COVID-19 on liver transplant recipients-A systematic review and meta-analysis.EClinicalMedicine. 2021 Aug;38:101025. doi: 10.1016/j.eclinm.2021.101025. Epub 2021 Jul 13. EClinicalMedicine. 2021. PMID: 34278287 Free PMC article.
References
-
- Kumar D., Ferreira V.H., Blumberg E., Silveira F., Cordero E., Perez-Romero P., et al. A 5-year prospective multicenter evaluation of influenza infection in transplant recipients. Clin Infect Dis. 2018;67:1322–1329. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous